Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.06.2010 | Preclinical study

Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma

verfasst von: Mohamed Kamal, Abeer M. Shaaban, Liqun Zhang, Clare Walker, Sally Gray, Nalin Thakker, Carmel Toomes, Valerie Speirs, Sandra M. Bell

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

CUB and SUSHI multiple domain protein 1 (CSMD1) is a candidate tumour suppressor gene that maps to chromosome 8p23, a region deleted in many tumour types including 50% of breast cancers. CSMD1 has homologies to proteins implicated in carcinogenesis. We aimed to study the expression pattern of the CSMD1 protein and evaluate its prognostic importance in invasive ductal carcinoma (IDC). An anti-CSMD1 antibody was developed and validated. The expression pattern of CSMD1 in normal breast and IDC samples was investigated by immunohistochemistry in 275 patients. Univariate and multivariate Cox regression analyses were performed. In normal breast duct epithelial cells, luminal, membranous and cytoplasmic CSMD1 staining was identified. Reduced expression of CSMD1 was detected in 79/275 (28.7%) of IDC cases. Low CSMD1 expression was significantly associated with high tumour grade (P = 0.003). CSMD1 expression was associated with overall survival (OS; HR = 0.607, 95%CI: 0.4–0.91, P = 0.018) but not with disease-free survival (DFS; HR = 0.81, 95%CI: 0.46–1.43, P = 0.48). Multivariate analysis showed that CSMD1, together with Nottingham Prognostic Index, was considered an independent predictor of OS (HR = 0.607, 95%CI: 0.4–0.91, P = 0.018) but not DFS (HR = 0.84, 95%CI: 0.46–1.5, P = 0.573). Reduction of CSMD1 expression was significantly associated with high tumour grade and decreased OS. Therefore, our results support the idea that CSMD1 is a tumour suppressor gene and suggest its possible use as a new prognostic biomarker. The membrane expression pattern of CSMD1 suggests that it may be a receptor or co-receptor involved in the process of signal transduction.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Sankila R, Ferlay J et al (2002) Estimates of cancer incidence, mortality in Europe in 1995. Eur J Cancer 38(1):99–166CrossRefPubMed Bray F, Sankila R, Ferlay J et al (2002) Estimates of cancer incidence, mortality in Europe in 1995. Eur J Cancer 38(1):99–166CrossRefPubMed
2.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94(2):153–156CrossRefPubMed Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94(2):153–156CrossRefPubMed
3.
Zurück zum Zitat Fabre-Lafay S, Monville F, Garrido-Urbani S et al (2007) Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 7(1):73CrossRefPubMed Fabre-Lafay S, Monville F, Garrido-Urbani S et al (2007) Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 7(1):73CrossRefPubMed
4.
Zurück zum Zitat Alford D, Taylor-papadimitrion J (1996) Cell adhesion molecules in the normal and cancerous mammary gland. J Mammary Gland Biol Neoplasia 1(2):207–218CrossRefPubMed Alford D, Taylor-papadimitrion J (1996) Cell adhesion molecules in the normal and cancerous mammary gland. J Mammary Gland Biol Neoplasia 1(2):207–218CrossRefPubMed
5.
Zurück zum Zitat Sun PC, Uppaluri R, Schmidt AP et al (2001) Transcript map of the 8p23 putative tumor suppressor region. Genomics 75(1–3):17–25CrossRefPubMed Sun PC, Uppaluri R, Schmidt AP et al (2001) Transcript map of the 8p23 putative tumor suppressor region. Genomics 75(1–3):17–25CrossRefPubMed
6.
Zurück zum Zitat Kirkitadze MarinaD, NB P (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180(1):146–161CrossRefPubMed Kirkitadze MarinaD, NB P (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180(1):146–161CrossRefPubMed
7.
Zurück zum Zitat Sigbjornsdottir BI, Ragnarsson G, Agnarsson BA et al (2000) Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet 37(5):342–347CrossRefPubMed Sigbjornsdottir BI, Ragnarsson G, Agnarsson BA et al (2000) Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet 37(5):342–347CrossRefPubMed
8.
Zurück zum Zitat Yokota T, Yashimoto M, Akiyama F et al (1999) Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cm interval of 8p22–p23.1. Cancer 85(2):447–452CrossRefPubMed Yokota T, Yashimoto M, Akiyama F et al (1999) Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cm interval of 8p22–p23.1. Cancer 85(2):447–452CrossRefPubMed
9.
Zurück zum Zitat Emi M, Fujiwara Y, Nakajima T et al (1992) Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 52(19):5368–5372PubMed Emi M, Fujiwara Y, Nakajima T et al (1992) Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 52(19):5368–5372PubMed
10.
Zurück zum Zitat Wu CL, Roz L, Sloan P et al (1997) Deletion mapping defines three discrete areas of allelic imbalance on chromosome arm 8p in oral and oropharyngeal squamous cell carcinomas. Genes. Chromosom Cancer 20(4):347–353CrossRef Wu CL, Roz L, Sloan P et al (1997) Deletion mapping defines three discrete areas of allelic imbalance on chromosome arm 8p in oral and oropharyngeal squamous cell carcinomas. Genes. Chromosom Cancer 20(4):347–353CrossRef
11.
Zurück zum Zitat Toomes C, Jackson A, Maguire K et al (2003) The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes. Chromosom Cancer 37(2):132–140CrossRef Toomes C, Jackson A, Maguire K et al (2003) The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes. Chromosom Cancer 37(2):132–140CrossRef
12.
Zurück zum Zitat Sunwoo JB, Holt MS, Radford DM et al (1996) Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. Genes Chromosomes Cancer 16(3):164–169CrossRefPubMed Sunwoo JB, Holt MS, Radford DM et al (1996) Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. Genes Chromosomes Cancer 16(3):164–169CrossRefPubMed
13.
Zurück zum Zitat Scholnick SB, Haughey BH, Sunwoo JB et al (1996) Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst 88(22):1676–1682CrossRefPubMed Scholnick SB, Haughey BH, Sunwoo JB et al (1996) Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst 88(22):1676–1682CrossRefPubMed
14.
Zurück zum Zitat Fujiwara Y, Emi M, Ohata H et al (1993) Evidence for the presence of two tumor Suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53(5):1172–1174PubMed Fujiwara Y, Emi M, Ohata H et al (1993) Evidence for the presence of two tumor Suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53(5):1172–1174PubMed
15.
Zurück zum Zitat Ishwad CS, Shuster M, Buckmuhl U et al (1999) Frequent allelic loss and homozygous deletion in chromosome band 8p23 in oral cancer. Int J Cancer 80(1):25–31CrossRefPubMed Ishwad CS, Shuster M, Buckmuhl U et al (1999) Frequent allelic loss and homozygous deletion in chromosome band 8p23 in oral cancer. Int J Cancer 80(1):25–31CrossRefPubMed
16.
Zurück zum Zitat Ma C, Quesnelle KM, Sparano A et al (2009) Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8(10):29–38 Ma C, Quesnelle KM, Sparano A et al (2009) Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 8(10):29–38
17.
Zurück zum Zitat Midorikawa Y, Yamamato S, Tsuji S et al (2008) Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology 49(2):513–522CrossRef Midorikawa Y, Yamamato S, Tsuji S et al (2008) Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology 49(2):513–522CrossRef
18.
Zurück zum Zitat Farrell LC, Crimm H, Meeh P et al (2008) Somatic mutations to CSMD1 in colorectal adenocarcinomas. Cancer Biol Ther 7(4):609–613PubMed Farrell LC, Crimm H, Meeh P et al (2008) Somatic mutations to CSMD1 in colorectal adenocarcinomas. Cancer Biol Ther 7(4):609–613PubMed
19.
Zurück zum Zitat Henshall SM, Afar DEH, Hiller J et al (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63(14):4196–4203PubMed Henshall SM, Afar DEH, Hiller J et al (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63(14):4196–4203PubMed
20.
Zurück zum Zitat Paris PL, Andaya A, Fridlyand J et al (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13(13):1303–1313CrossRefPubMed Paris PL, Andaya A, Fridlyand J et al (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13(13):1303–1313CrossRefPubMed
21.
Zurück zum Zitat Nishioka M, Kohno T, Takahashi M et al (2000) Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene 19(54):6251–6260CrossRefPubMed Nishioka M, Kohno T, Takahashi M et al (2000) Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene 19(54):6251–6260CrossRefPubMed
22.
Zurück zum Zitat Kraus DM, Elliott GS, Chute H et al (2006) CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol 176(7):4419–4430PubMed Kraus DM, Elliott GS, Chute H et al (2006) CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. J Immunol 176(7):4419–4430PubMed
23.
Zurück zum Zitat Mollenhauer J, Wiemann S, Scheurlen W et al (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours. Nat Genet 17(1):32–39CrossRefPubMed Mollenhauer J, Wiemann S, Scheurlen W et al (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours. Nat Genet 17(1):32–39CrossRefPubMed
24.
Zurück zum Zitat Wu W, Kemp BL, Proctor ML et al (1999) Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 59(8):1846–1851PubMed Wu W, Kemp BL, Proctor ML et al (1999) Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 59(8):1846–1851PubMed
25.
Zurück zum Zitat Mollenhauer J, Helmke B, Medina D et al (2004) Carcinogen inducibility in vivo and down-regulation of DMBT1 during breast carcinogenesis. Genes Chromosom Cancer 39(3):185–194CrossRefPubMed Mollenhauer J, Helmke B, Medina D et al (2004) Carcinogen inducibility in vivo and down-regulation of DMBT1 during breast carcinogenesis. Genes Chromosom Cancer 39(3):185–194CrossRefPubMed
26.
Zurück zum Zitat Bork P, Beckmann G (1993) The CUB domain: a widespread module in developmentally regulated proteins. J Mol Biol 231(2):539–545CrossRefPubMed Bork P, Beckmann G (1993) The CUB domain: a widespread module in developmentally regulated proteins. J Mol Biol 231(2):539–545CrossRefPubMed
27.
Zurück zum Zitat Topfer-Petersen E, Romero A, Varela PF et al (1998) Spermadhesins: a new protein family. Facts, hypotheses and perspectives. Andrologia 30(4–5):217–224PubMed Topfer-Petersen E, Romero A, Varela PF et al (1998) Spermadhesins: a new protein family. Facts, hypotheses and perspectives. Andrologia 30(4–5):217–224PubMed
28.
Zurück zum Zitat Lu S-L, Kawabata M, Imamura T et al (1998) HNPCC associated with germline mutation in the TGF-[beta] type II receptor gene. Nat Genet 19(1):17–18CrossRefPubMed Lu S-L, Kawabata M, Imamura T et al (1998) HNPCC associated with germline mutation in the TGF-[beta] type II receptor gene. Nat Genet 19(1):17–18CrossRefPubMed
29.
Zurück zum Zitat Su GH, Bansal R, Murphy KM et al (2001) ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A 98(6):3254–3257CrossRefPubMed Su GH, Bansal R, Murphy KM et al (2001) ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A 98(6):3254–3257CrossRefPubMed
30.
Zurück zum Zitat Williams LM, Drew JE, Bunnett NW et al (2001) Characterization of an antibody to the human melatonin mt1 receptor. J Neuroendocrinol 13(1):94–101CrossRefPubMed Williams LM, Drew JE, Bunnett NW et al (2001) Characterization of an antibody to the human melatonin mt1 receptor. J Neuroendocrinol 13(1):94–101CrossRefPubMed
31.
Zurück zum Zitat Muscheck M, Sukosd F, Pesti T et al (2000) High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p23.3. Lab Invest 80(7):1089–1093PubMed Muscheck M, Sukosd F, Pesti T et al (2000) High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p23.3. Lab Invest 80(7):1089–1093PubMed
32.
Zurück zum Zitat Washburn JG, Wojno KJ, Dey J et al (2000) 8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res 6(12):4647–4652PubMed Washburn JG, Wojno KJ, Dey J et al (2000) 8pter-p23 deletion is associated with racial differences in prostate cancer outcome. Clin Cancer Res 6(12):4647–4652PubMed
33.
Zurück zum Zitat Bockmühl U, Ishwad CS, Ferrell RE et al (2001) Association of 8p23 deletions with poor survival in head and neck cancer. Otolaryngol Head Neck Surg 124(4):451–455CrossRefPubMed Bockmühl U, Ishwad CS, Ferrell RE et al (2001) Association of 8p23 deletions with poor survival in head and neck cancer. Otolaryngol Head Neck Surg 124(4):451–455CrossRefPubMed
34.
Zurück zum Zitat Weber-Mangal S, Sinn H, Popp S et al (2003) Breast cancer in young women (< or =35 years): genomic aberrations detected by comparative genomic hybridization. Int J Cancer 107(4):583–592CrossRefPubMed Weber-Mangal S, Sinn H, Popp S et al (2003) Breast cancer in young women (< or =35 years): genomic aberrations detected by comparative genomic hybridization. Int J Cancer 107(4):583–592CrossRefPubMed
35.
Zurück zum Zitat Wright K, Wilson PJ, Kerr J et al (1998) Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 17(9):1185–1188CrossRefPubMed Wright K, Wilson PJ, Kerr J et al (1998) Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 17(9):1185–1188CrossRefPubMed
36.
Zurück zum Zitat Paccaud JP, Reith W, Johansson B et al (1993) Clathrin-coated pit-mediated receptor internalization. Role of internalization signals and receptor mobility. J Biol Chem 268(31):23191–23196PubMed Paccaud JP, Reith W, Johansson B et al (1993) Clathrin-coated pit-mediated receptor internalization. Role of internalization signals and receptor mobility. J Biol Chem 268(31):23191–23196PubMed
37.
Zurück zum Zitat Richter T, Tong B, Scholnick S (2005) Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int 5(1):29CrossRefPubMed Richter T, Tong B, Scholnick S (2005) Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int 5(1):29CrossRefPubMed
Metadaten
Titel
Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma
verfasst von
Mohamed Kamal
Abeer M. Shaaban
Liqun Zhang
Clare Walker
Sally Gray
Nalin Thakker
Carmel Toomes
Valerie Speirs
Sandra M. Bell
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0500-4

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.